These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18463333)

  • 1. FDA approves pharmacologic stress agent.
    Thompson CA
    Am J Health Syst Pharm; 2008 May; 65(10):890. PubMed ID: 18463333
    [No Abstract]   [Full Text] [Related]  

  • 2. Regadenoson long-lasting use induced tachyarrythmia.
    Ramos-Font C; Jimenez-Heffernan A; González Jimenez A; Rashki M; Llamas Elvira JM
    J Nucl Cardiol; 2019 Jun; 26(3):1036-1039. PubMed ID: 30565060
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete heart block associated with regadenoson: a real side effect.
    Pandit A; Unzek Freiman S
    J Nucl Cardiol; 2012 Dec; 19(6):1236-9. PubMed ID: 22915132
    [No Abstract]   [Full Text] [Related]  

  • 4. Myocardial Stress Perfusion MRI: Experience in Pediatric and Young-Adult Patients Following Arterial Switch Operation Utilizing Regadenoson.
    Noel CV; Krishnamurthy R; Masand P; Moffett B; Schlingmann T; Cheong BY; Krishnamurthy R
    Pediatr Cardiol; 2018 Aug; 39(6):1249-1257. PubMed ID: 29748700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
    Salgado-Garcia C; Jimenez-Heffernan A; Lopez-Martin J; Molina-Mora M; Aroui T; Sanchez de Mora E; Ramos-Font C; Rivera de Los Santos F; Ruiz-Frutos C
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1906-1914. PubMed ID: 28547175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QTc prolongation after regadenoson administration.
    Gupta A; Borer S; Heller GV
    J Nucl Cardiol; 2012 Oct; 19(5):1080-2. PubMed ID: 22700005
    [No Abstract]   [Full Text] [Related]  

  • 7. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary vasospasm during a regadenoson stress test.
    Bagley SJ; Lilly SM; Litwack AJ
    Cardiol J; 2012; 19(1):92-4. PubMed ID: 22298176
    [No Abstract]   [Full Text] [Related]  

  • 9. Adenosine receptors as drug targets--what are the challenges?
    Chen JF; Eltzschig HK; Fredholm BB
    Nat Rev Drug Discov; 2013 Apr; 12(4):265-86. PubMed ID: 23535933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
    Qamruddin S; Huang HW; Mehra A; Bonyadlou S; Yoon AJ
    Clin Nucl Med; 2016 Jan; 41(1):62-4. PubMed ID: 26447370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does a shortened hyperemia with regadenoson stress pose a concern for quantitative Rb-82 PET imaging? Optimization of regadenoson PET imaging.
    Sinusas AJ
    JACC Cardiovasc Imaging; 2015 Apr; 8(4):448-450. PubMed ID: 25882574
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve.
    Arumugham P; Figueredo VM; Patel PB; Morris DL
    EuroIntervention; 2013 Feb; 8(10):1166-71. PubMed ID: 23164748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Asystole after regadenoson administration to perform a myocardial perfusion imaging test].
    Briegas Morera D; Martín Clavo S; Estepa Alonso MJ; Rangel Mayoral JF
    Farm Hosp; 2017 Jul; 41(4):563-564. PubMed ID: 28683710
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA approves first celecoxib generics.
    Kuehn BM
    JAMA; 2014 Jun; 311(24):2470. PubMed ID: 25058066
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in pharmacologic stress agents: focus on regadenoson.
    Johnson SG; Peters S
    J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson.
    Noel CV; Krishnamurthy R; Moffett B; Krishnamurthy R
    Pediatr Radiol; 2017 Mar; 47(3):280-289. PubMed ID: 28035425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced heart block and unresponsiveness after regadenoson administration during myocardial SPECT study.
    Agarwal V; DePuey EG
    Int J Cardiol; 2014 Sep; 176(2):e49-51. PubMed ID: 25107448
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons from the development of new adenosine A2A receptor agonists.
    Udelson JE
    JACC Cardiovasc Imaging; 2008 May; 1(3):317-20. PubMed ID: 19356443
    [No Abstract]   [Full Text] [Related]  

  • 19. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regadenoson-induced bradycardia and hypotension: possible mechanism and antidote.
    Underwood SR; Latus KA; Reyes E; Standbridge K; Walker S; Wechalekar K
    J Nucl Cardiol; 2014 Oct; 21(5):1040. PubMed ID: 25150094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.